Overview
NRSN market data
Price History
NRSN price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for NRSN. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS MeetingBenzinga · Jul 22, 2026, 12:38 PM
NeuroSense Therapeutics Announces Its Phase 2B PARADIGM Study Of PrimeC In Amyotrophic Lateral Sclerosis Has Met Its Primary Efficacy EndpointBenzinga · Jun 29, 2026, 1:40 PM
NeuroSense Therapeutics Announces Data From Its Phase 2 RoAD Trial Of PrimeC In Alzheimer's Disease Demonstrates Multiple Protein Biomarker Changes; Distinctive Changes Also Seen In Levels Of Other Major Neurodegenerative Disease Misfolding ProteinsBenzinga · Jun 25, 2026, 1:25 PM
NeuroSense Therapeutics Secures Japanese Patent 7857044 Covering Its Lead Drug Candidate For Treatment Of Amyotrophic Lateral SclerosisBenzinga · Jun 9, 2026, 1:15 PM